This page shows the latest apixaban news and features for those working in and with pharma, biotech and healthcare.
In addition to $13bn in sales from Comirnaty, anticoagulant Eliquis (apixaban) grew by 19% to $1.3bn, amyloidosis therapy Vyndaqel/Vyndamax (tafamidis) was up by 42% to $502m and Inlyta increased
The drivers of growth were multiple myeloma drug Revlimid (lenalidomide), which saw sales of $3.34bn (up by 11%), blood-thinner Eliquis (apixaban) with $2.41bn (up by 15%) and cancer
This includes the company’s oral anticoagulant Eliquis (apixaban), BMS’ second biggest product after cancer immunotherapy Opdivo (nivolumab). ... Although BMS maintained at the time that the patent for composition of matter covering apixaban in the
The positive quarterly results build on BMS’ key patent challenge victory on Wednesday for its blood thinner Eliquis (apixaban). ... While subject to appeal, at present the generic manufacturers currently involved in the case cannot launch their
BMS’ well-established anticoagulant Eliquis (apixaban) had another strong quarter with a 19% rise to just over $2bn, while multiple myeloma drug Empliciti (elotuzumab) grew by more than a third to
ago. Meanwhile, vaccine blockbuster Prevnar also continued its slowdown, but still brought in $1.58bn in the quarter, and anticoagulant Eliquis (apixaban) continued its strong growth with a 21% gain to
More from news
Approximately 9 fully matching, plus 87 partially matching documents found.
merger. 106. † Portola Pharmaceuticals/ BMS| Pfizer. andexanet alfa as an antidote for apixaban and other Factor Xa inhibitors (pre-reg).
Apixaban. Bristol-Myers Squibb and Pfizer are developing apixaban (Eliquis), which is an oral, twice-daily, selective factor Xa inhibitor. ... statistically significant reduction in mortality was also observed in apixaban recipients in this trial.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Puneet Mohan (left) comes to PPD from Bristol-Myers Squibb, where he most recently served as executive director of global clinical development and global clinical leader for Eliquis (apixaban).
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
There was also a greater number of generic products. Anticoagulant therapies such as apixaban, rivaroxaban and edoxaban topped the spending charts, while respiratory products such as inhalable treatments for asthma and
This was followed by anti-coagulant medication (£740 million), where there were notable increases in spending on drugs such as apixaban (up 16 per cent), rivaroxaban (up 5.1 per cent)
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Origins creates and delivers patient focused strategy, insights, data and solutions, which guides pharma and biotech companies to improve value...